Macro Economic Group - The US manufacturing sector continues to contract, with the ISM manufacturing PMI for June at 49, indicating a decline for four consecutive months. New orders index dropped to 46.4, reflecting the largest decrease in three months [3][4] - Manufacturing output returned to expansion at 50.3 in June after three months of contraction, driven by domestic and export orders, although this improvement may be partly due to inventory accumulation in response to rising tariffs [3] - Employment index fell to 45, marking a three-month low, and the price index reached 69.7, indicating ongoing cost pressures for manufacturers [4] Industry Comprehensive Group - The Central Financial Committee's recent meeting emphasized the need for a unified national market and high-quality development of the marine economy, suggesting a potential delay in economic stimulus policies due to better-than-expected economic performance in the first half of the year [7] - The focus on regulating low-price competition among enterprises may enhance market expectations for reduced competition in highly saturated industries and increased policy support for the marine economy, potentially creating investment opportunities [7] Advanced Manufacturing Group - In June, China's heavy truck market saw wholesale sales of 92,000 units, a 4% month-on-month increase and a 29% year-on-year surge, indicating a recovery trend in the industry [10] - Electric heavy trucks have gained significant traction, with sales exceeding 15,000 units in June, representing over a 120% year-on-year growth, and a domestic penetration rate exceeding 24% [10][11] - The demand for heavy trucks is being driven by a vehicle replacement policy, although challenges remain in the freight market, including low prices and tight supply [11] Consumer Group - Jinbo Biological announced a targeted fundraising of 2 billion yuan, with strategic partnerships expected to enhance its market presence and production capabilities in the collagen protein sector [13] - The collaboration with Yangshengtang and the experience of Wan Tai Biological in international markets may facilitate Jinbo Biological's expansion and product commercialization [13]

Investment Rating - The investment rating for the company is maintained as "Buy" [2] Core Views - The prices of the main products, Vitamin B1 and B6, remain strong, contributing to profit growth. The company is a significant supplier in the global B vitamin market, holding leading market shares in Vitamin B6 and B1, with a revenue contribution of 78% from B vitamins in 2024. The prices for Vitamin B6 and B1 have shown year-on-year increases of 43.8% and 21.04% respectively in the first half of 2025, driving rapid profit growth [8][5] - The company is expanding its product line with new projects, including Vitamin B5 and Vitamin A, which are expected to enhance its long-term growth potential. The successful launch of these new products could significantly increase the company's market presence [8] - The financial forecast has been slightly adjusted, with expected net profits for 2025, 2026, and 2027 projected at 921 million, 1,063 million, and 1,070 million respectively. The corresponding PE ratios are estimated at 13, 11, and 11 times. The target market value for 2025 is set at 141 billion, indicating a 21% upside potential from the current market value [8][10] Financial Data and Profit Forecast - Total revenue is projected to grow from 2,209 million in 2024 to 2,708 million in 2025, with a year-on-year growth rate of 22.6%. The net profit is expected to increase from 651 million in 2024 to 921 million in 2025, reflecting a growth rate of 41.4% [7][12] - The gross margin is anticipated to improve from 42% in 2024 to 51.1% in 2025, while the return on equity (ROE) is expected to rise from 14.1% to 16.6% during the same period [7][12]

Group 1: Investor Relations Activity Overview - The investor relations activity was conducted on May 15, 2025, at Chengdu Oukang Pharmaceutical Co., Ltd. [3] - Attendees included representatives from Kaiyuan Securities, Huayuan Securities, Zhongrui Huyin, and Luxin Chuangtou [3] - Company representatives included Chairman Zhao Zhuojun and CFO Cao Yongqiang [3] Group 2: Impact of Industry Trends - The overall price decline in the vitamin industry has limited impact on the company's product pricing, which is primarily influenced by raw material supply and market demand [5] - The company specializes in flavonoid products, a niche within the vitamin sector, using raw materials like bitter orange and sophora flower [5] Group 3: Production Capacity and Utilization - The new plant's production lines for bitter orange are expected to achieve over 50% capacity utilization by the end of 2025 [6] - The production lines for sophora flower are also projected to reach 50% capacity utilization by year-end 2025, with a focus on fine management and market expansion [6] Group 4: Market Expansion and Partnerships - The company has established strong partnerships in Japan for its sophora flower and bitter orange products, focusing on the food additive and health product markets [7] - Ongoing efforts are being made to deepen cooperation with clients and expand market influence in Japan [7] Group 5: Facility Upgrades and Compliance - Upgrades to the Diosmin and Rutin production lines have been completed, meeting both domestic and international GMP standards [8] - The upgraded lines have passed domestic GMP compliance checks and are in the process of obtaining EuGMP certification [8] Group 6: Financial Projections - The company anticipates a 160% increase in depreciation expenses for 2025 compared to 2024 due to the completion of investment projects [9] - Strategies will be implemented to enhance sales revenue to offset increased depreciation costs [9] Group 7: Profitability and Market Trends - The company's gross margin has declined due to production challenges and increased costs in Q1 2025, but is expected to recover as production lines stabilize [11] - The market for quercetin is projected to grow significantly due to rising health awareness and demand for natural ingredients, particularly in health supplements and functional foods [12]

近日， 【SynBioCon】 获 悉，" 维生素的高效异源合成 "是 国家重点研发计划"合成生物学"专项2024年度立项项目，由 四川大学牵头、轻工科学 与工程学院许正宏教授担任项目负责人，4月25日在成都召开 项目启动暨实施方案论证会，会议邀请了 四川大学石碧院士、 四川省科学技术厅陈学华 副厅长、四川大学刘超副校长等多位 领导和行业权威专家 共同研讨项目实施方案。 该项目包含 4个方向 ：" 维生素异源合成途径设计与优化" 、" 关键酶的机理解析与设计改造 "、" 高效异源合成细胞工厂的构建与精准调控 "、" 维 生素绿色智能制造及产业化示范 "。 本次会议的召开标志着"维生素的高效异源合成"项目正式进入全面实施阶段 。项目团队将按照专家意见进一步完善研究方案，加强协同创新，力争在 维生素生物合成领域取得突破性进展，为我国生物制造产业发展贡献力量。 01 热点赛道：维生素+合成生物，国内企业乘势而上 根据其溶解性，维生素分为 水溶性维生素 和 脂溶性维生素 两大类。 脂溶性维生素（ 维生素 A、维生素 D 、维生 素 E 和维生素 K ）具有非常广阔 的市场前景，目前维生素A以及维生素E占有约45%的市 ...